Publication Date: 2015-03-14
by Jeffrey Wang, Wei-Chiang Shen, and Jennica L. Zaro
volume provides a holistic picture of antibody-drug conjugates (ADCs).
Fourteen comprehensive chapters are divided into six sections including an
introduction to ADCs, the ADC construct, development issues, landscape, IP and
pharmacoeconomics, case studies, and the future of the field. The book
examines everything from the selection of the antibody, the drug, and the
linker to a discussion of developmental issues such as formulations,
bioanalysis, pharmacokinetic-pharmacodynamic relationships, and toxicological
and regulatory challenges. It also explores pharmacoecomonics and intellectual
properties, including recently issued patents and the cost analysis of drug
therapy. Case studies are presented for the three ADCs that have received Food
and Drug Administration approval: gemtuzumab ozogamicin (Mylotarg),
Brentuximab vedotin (Adcetris), and ado-trastuzumab emtansine (Kadcyla), as
well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011).
Finally, the volume presents a perspective by the editors on the future
directions of ADC development and clinical applications. Antibody-Drug
Conjugates is a practical and systematic resource for scientists,
professors, and students interested in expanding their knowledge of
cutting-edge research in this exciting field.
Hardcover suggested list price:
View other format pricing, and order a copy on the Springer website today!
Members—Sign in to view your 25% discount token here. Then, go to the Springer website to order a copy using your token.